Elsevier

Lung Cancer

Volume 141, March 2020, Pages 56-63
Lung Cancer

Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer

https://doi.org/10.1016/j.lungcan.2019.12.008Get rights and content

Highlights

  • "Biopsy techniques influence the detection of moleculargenetic alterations".

  • "Cryobiopsy showed a higher detection rate of EGFR mutations than other techniques".

  • “Cryobiopsy may optimize individualized NSCLC treatment”.

Abstract

Objectives

Detection of activating epidermal growth factor receptor (EGFR) mutation is crucial for individualized treatment of advanced non-small-cell lung cancer (NSCLC). However little is known about how biopsy technique affects the detection rate of EGFR mutations. This retrospective, single center study evaluated the detection rate of EGFR mutations in tissue obtained by bronchoscopic cryobiopsy and compared this to other standard tissue sampling techniques.

Materials and methods

We retrospectively analyzed 414 patients with histologically confirmed NSCLC and known EGFR mutation status between 3/2008-7/2014. Tumor specimens obtained by tissue preserving bronchoscopic cryobiopsy were compared to those obtained by other techniques.

Results and conclusion

Analysis of bronchoscopic cryobiopsy tissue detected 29 activating EGFR mutations in 27 (21.6 %) out of 125 patients, while analysis of tissue obtained by non-cryobiopsy techniques (bronchoscopic forceps biopsies, fine needle aspiration, imaging guided transthoracical and surgical procedures) detected 42 EGFR mutations in 40 (13.8 %) out of 298 patients (p < 0.05). Cryobiopsy increased detection rate of EGFR mutations in central tumors compared with forceps biopsy (19.6 % versus 6.5 %, p < 0.05), while an insignificant trend was detected also for peripheral tumors (33.3 % versus 26.9 %).

Bronchosopic cryobiopsy increases the detection rate of activating EGFR mutations in NSCLC in comparison to other tissue sampling techniques. This will help to optimize individualized treatment of patients with advanced tumors. Because of the retrospective nature of this analysis, a prospective trial is mandatory for final assessment.

Introduction

Lung cancer ranks among the most common cancers worldwide with approximately 1.8 million patients in 2012 [1,2]. Non small cell lung cancer (NSCLC) represents 75–85 % of all lung cancers. 2/3 of these patients are in non-curable stage III and IV at the time of diagnosis, and are usually treated systemically [3]. The current management of non-curable NSCLC has become more and more individualized and is based on immunohistochemical and molecular tumor characterization [4]. In this context, EGFR mutation is currently the most relevant molecular-genetic alteration [5] since target therapies directed to activating EGFR mutation not only have a much better side effect profile [6], but also lead to an improved clinical response [7], an improved progression free survival, and an improved overall survival in certain subgroups (e.g. with deletion in Exon 19 [[8], [9], [10], [11], [12], [13], [14]]).

As a consequence, precise and correct molecular characterization of advanced stage III and IV NSCLC is crucial for ensuring optimal treatment, and missing any targetable alteration may result in suboptimal therapy. Therefore, representative tumour tissue of adequate volume and quality forms the basis for optimal histological and molecular evaluation. EGFR testing lays the cornerstone for current NSCLC treatment in advanced stages [15]. Apart from surgical resection and radiologically guided biopsies, the standard techniques to obtain tissue samples in patients with suspected lung cancer are bronchoscopic forceps biopsy and fine needle aspiration [16]. However, there has been no detailed evaluation of the quality of biopsy specimen required for molecular testing, nor has there been an evaluation as to which biopsy technique provides the best material for molecular testing. As a result, guidelines on molecular testing of NSCLC do not discuss the quality of biopsy specimens required for EGFR testing, and limit their recommendations to statements like “a sufficient cancer cell content and appropriate DNA quantity and quality” [17,18] are required. This had led to the imprecise advice that each laboratory defines its own criteria [17]. Even in prospective large multicentre trials evaluating the effect of targeted therapies, criteria addressing the quality of biopsy specimens needed for molecular testing are usually not specified [19].

The recently developed technique of cryobiopsy for the diagnosis of patients with endobronchial tumor has revealed a significantly higher diagnostic yield for lung cancer than conventional forceps biopsy [20]. In addition, cryobiopsy samples are of sufficiently large size to routinely allow immunohistological staining [21]. Cryobiopsy provides better tissue preservation without biopsy artifacts. Nevertheless, it cannot be ruled out that physical alterations caused by the freezing and thawing cycle during cryobiopsy could influence the diagnostic value on a molecular level.

We have therefore evaluated the detection rate of EGFR mutations in cryobiopsies and compared these to other biopsy techniques in patients with pathologically proven non small cell lung cancer.

Section snippets

Study design and population

This retrospective single center study was performed at the Department of Internal Medicine II in collaboration with the Institute of Pathology at the University of Tuebingen, Germany. All malignant tissue samples from the University Hospital which had been examined for EGFR mutations between March 2008 and July 2014 were included in this study. A total of 483 tissue samples were analyzed for mutations of the EGFR gene on exon 18, 19, 20, 21 using Sanger sequencing [22]. 60 tumor samples were

Patient characteristics

Demographic data of the cryobiopsy group and the non-cryobiopsy group were comparable with regard to age and gender, as shown in Table 1. Almost all patients were Causasian (>99 %). Due to the retrospective study design smoking status was unknown in a large proportion of patients, but when known, it did not differ between both groups.

Tumor characteristics

Tumor characteristics for both groups are shown in Table 2. Cryobiopsy was used more frequently for sampling of central tumors (85.6 %), while non-cryobiopsy

Discussion

To our knowledge, this is the first analysis to study the influence of biopsy techniques on the rate of EGFR mutation detection in patients with NSCLC. Our restrospective analysis indicates that sampling by bronchoscopic cryobiopsy increased the detection rate of molecular genetic alterations in NSCLC in comparison to other biopsy techniques (21.6 % vs 13.8 % (p < 0.05). Thus cryobiopsy might be able to substantially increase the number of patients who go on to receive targeted therapy.

EGFR

Authors’ contributions

MH contributed to the concept, performed the bronchoscopic procedures, analyzed the data, performed statistical analysis and wrote the main part of the manuscript. MB contributed to the concept and performed the bronchoscopic procedures. AE analyzed the data and contributed to the manuscript. RW analyzed the data and performed statistical analysis. W.S. performed the bronchoscopic procedures. V.S. performed the surgical procedures. H.B. and F.F. did the histopathological evaluation. MHo

Declaration of Competing Interest

JH has received personal fees from Erbe Elektromedizin GmbH for workshops and presentations. MH and MB have received personal fees from Erbe Elektromedizin GmbH for Workshops. AE, RW, WS, VS, HB, MHo, RAL, FF, LK, IB have no conflict of interest to declare.

References (64)

  • Q. Pan et al.

    Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

    J. Mol. Diagn.

    (2005)
  • K. Endo et al.

    Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay

    Lung Cancer (Amsterdam, Netherlands)

    (2005)
  • M. Akbari et al.

    Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner

    J. Mol. Diagn.

    (2005)
  • C. Wong et al.

    Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation

    Cancer Genet. Cytogenet.

    (1998)
  • C. Williams et al.

    A high frequency of sequence alterations is due to formalin fixation of archival specimens

    Am. J. Pathol.

    (1999)
  • N.L. Sieben et al.

    PCR artifacts in LOH and MSI analysis of microdissected tumor cells

    Hum. Pathol.

    (2000)
  • K. Arimura et al.

    Cryobiopsy with endobronchial ultrasonography using a guide sheath for peripheral pulmonary lesions and DNA analysis by next generation sequencing and rapid on-site evaluation

    Respir. Investig.

    (2019)
  • R. Siegel et al.

    Cancer statistics, 2014

    CA Cancer J. Clin.

    (2014)
  • A. Jemal et al.

    Cancer statistics, 2009

    CA Cancer J. Clin.

    (2009)
  • D.L. Aisner et al.

    Molecular pathology of non-small cell lung cancer: a practical guide

    Am. J. Clin. Pathol.

    (2012)
  • T.J. Lynch et al.

    Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

    N. Engl. J. Med.

    (2004)
  • J.G. Paez et al.

    EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

    Science

    (2004)
  • R. Rosell et al.

    Screening for epidermal growth factor receptor mutations in lung cancer

    N. Engl. J. Med.

    (2009)
  • M. Fukuoka et al.

    Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)

    J. Clin. Oncol.

    (2011)
  • L.V. Sequist et al.

    Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

    J. Clin. Oncol.

    (2013)
  • J.C. Yang et al.

    Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

    J. Clin. Oncol.

    (2013)
  • L.M. Ofiara et al.

    Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer

    Front. Oncol.

    (2014)
  • N.B. Leighl et al.

    Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline

    J. Clin. Oncol.

    (2014)
  • M.G. Kris et al.

    Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

    Jama

    (2014)
  • J. Hetzel et al.

    Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial

    Eur. Respir. J.

    (2012)
  • J. Hetzel et al.

    Old meets modern: the use of traditional cryoprobes in the age of molecular biology

    Respiration

    (2008)
  • F. Sanger et al.

    DNA sequencing with chain-terminating inhibitors

    Proc. Natl. Acad. Sci. U. S. A.

    (1977)
  • Cited by (0)

    View full text